RecruitingPhase 2

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

United States20 participantsStarted 2021-05-21

Plain-language summary

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Who can participate

Age range

60 Years – 95 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors: * MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0. * Memory, processing speed, executive function, language - cognitive scores \> 1.5 standard deviations below age-education norms. * Not demented by history. * Not taking statins currently or in the last 6 months. * Cognitive/functional impairment not likely due to another neurological disease or delirium. Exclusion Criteria: * Taking a statin currently or have taken a statin in the last 6 months. * Contraindications to taking a statin. * Transplant patient taking cyclosporine. * Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal). * Diagnosis of dementia by history. * Current diagnosis of substance abuse. * History of stroke or myocardial infarction in past 6 months. * History of HIV.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change of MRI whole brain cerebrovascular reactivity (wbCVR)

Timeframe: Baseline and 12 weeks

Trial details

NCT IDNCT04765137

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-07-31

Contact for this trial

Samantha Horn

410-550-9020 shorn8@jhmi.edu

View on ClinicalTrials.gov More Mild Cognitive Impairment trials

Who can participate

Age range

60 Years – 95 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.